EverSource Wealth Advisors
CRVS icon

EverSource Wealth Advisors’s Corvus Pharmaceuticals CRVS Stock Holding History

EverSource Wealth Advisors’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-60
Closed -$321 – 4052
2024
Q4 		$321 Buy
+60
New +$448 ﹤0.01% 3323

Other funds holding CRVS

OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Samlyn Capital
Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $643M AUM 343.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EverSource Wealth Advisors's CRVS Position: Q1 2025 in Review

EverSource Wealth Advisors sold out of Corvus Pharmaceuticals (CRVS) in Q1 2025, closing a stake of 60 shares — an estimated $321 sold.

EverSource Wealth Advisors first reported a position in CRVS in Q4 2024 and held it in 1 quarter. The position peaked at $321 in Q4 2024. 88 funds tracked by Wall St. Rank hold CRVS as of Q1 2025.

  • EverSource Wealth Advisors reported no remaining Corvus Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • EverSource Wealth Advisors sold 60 Corvus Pharmaceuticals shares in Q1 2025, an estimated $321.
  • EverSource Wealth Advisors first reported a position in Corvus Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • EverSource Wealth Advisors's Corvus Pharmaceuticals position peaked at $321 in Q4 2024.
  • 88 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2025.

Based on EverSource Wealth Advisors's 13F filing for Q1 2025, filed 13 May 2025.